A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Summary
Third Opinion Trial Synopsis:
Scientists are conducting a study to see if a new drug called tiragolumab is safe and effective for treating relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. They will be testing it on its own or in combination with other drugs, including atezolizumab, daratumumab, or rituximab.
Scientists are conducting a study to see if a new drug called tiragolumab is safe and effective for treating relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. They will be testing it on its own or in combination with other drugs, including atezolizumab, daratumumab, or rituximab.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.